Sionna Therapeutics (NASDAQ:SION) Director Sells $2,664,412.86 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 59,767 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $44.58, for a total transaction of $2,664,412.86. Following the completion of the transaction, the director directly owned 2,856,461 shares of the company’s stock, valued at approximately $127,341,031.38. This represents a 2.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Price Performance

NASDAQ:SION opened at $43.12 on Thursday. Sionna Therapeutics, Inc. has a 1-year low of $11.77 and a 1-year high of $48.44. The firm has a 50 day simple moving average of $39.11 and a 200-day simple moving average of $39.51. The firm has a market cap of $1.95 billion, a PE ratio of -22.34 and a beta of 1.35.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). As a group, sell-side analysts expect that Sionna Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on SION shares. JonesTrading boosted their target price on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Wedbush started coverage on shares of Sionna Therapeutics in a report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 target price for the company. UBS Group restated a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. Citizens Jmp started coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, Sionna Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $53.00.

Trending Headlines about Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Sionna Therapeutics and kept a $58 price target, implying meaningful upside from recent trading levels and reinforcing optimism around the company’s clinical pipeline. Article Title
• Positive Sentiment: Sionna Therapeutics said management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 20, which can give investors a fresh update on the company’s cystic fibrosis programs and keep attention on the story. Article Title
• Neutral Sentiment: In its first-quarter update, the company said enrollment is complete in the PreciSION CF Phase 2a trial for SION-719 and that topline data is expected in summer 2026, while the SION-451 Phase 1 study is also on track. It also reported a strong cash balance of about $289.9 million, supporting operations into 2028. Article Title
• Negative Sentiment: Sionna reported a first-quarter loss of $0.60 per share, wider than the expected $0.52 loss, which may weigh on sentiment even though the company remains pre-revenue and focused on clinical development. Article Title
• Negative Sentiment: Director OrbiMed Advisors and director Peter A. Thompson disclosed several large share sales in recent days. The transactions were made under pre-arranged 10b5-1 plans, but the size of the selling can still pressure investor sentiment. Article Title

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SION. Eventide Asset Management LLC purchased a new position in shares of Sionna Therapeutics in the fourth quarter valued at $26,290,000. Vanguard Group Inc. boosted its stake in shares of Sionna Therapeutics by 81.4% in the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after purchasing an additional 512,803 shares during the period. State Street Corp boosted its stake in shares of Sionna Therapeutics by 188.7% in the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after purchasing an additional 453,196 shares during the period. Jennison Associates LLC boosted its stake in shares of Sionna Therapeutics by 30.1% in the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after purchasing an additional 335,942 shares during the period. Finally, Viking Global Investors LP boosted its stake in shares of Sionna Therapeutics by 8.2% in the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares during the period.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.